{
  "resourceType" : "ActivityDefinition",
  "id" : "RezidivtherapieMitBTKbeiCLL",
  "meta" : {
    "profile" : ["https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/drug-administration-action"]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ActivityDefinition RezidivtherapieMitBTKbeiCLL</b></p><a name=\"RezidivtherapieMitBTKbeiCLL\"> </a><a name=\"hcRezidivtherapieMitBTKbeiCLL\"> </a><a name=\"RezidivtherapieMitBTKbeiCLL-en-US\"> </a><p><b>knowledgeCapability</b>: computable</p><p><b>knowledgeRepresentationLevel</b>: structured</p><p><b>url</b>: <a href=\"ActivityDefinition-RezidivtherapieMitBTKbeiCLL.html\">ActivityDefinition Rezidivtherapie mit BTK-Inhibitor bei CLL</a></p><p><b>version</b>: Langversion 2.01</p><p><b>name</b>: RezidivtherapieMitBTKbeiCLL</p><p><b>title</b>: Rezidivtherapie mit BTK-Inhibitor bei CLL</p><p><b>status</b>: Active</p><p><b>experimental</b>: false</p><p><b>subject</b>: <span title=\"Codes:{http://hl7.org/fhir/fhir-types Patient}\">Patient</span></p><p><b>date</b>: 2025-01-16 09:02:23+0000</p><p><b>publisher</b>: https://www.leitlinienprogramm-onkologie.de/leitlinien/s3-leitlinie-zur-diagnostik-therapie-und-nachsorge-fuer-patienten-mit-einer-chronischen-lymphatischen-leukaemie-cll</p><p><b>description</b>: </p><div><p>Rezidivtherapie mit BTK-Inhibitor bei CLL</p>\n</div><p><b>kind</b>: MedicationRequest</p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>product</b>: <span title=\"Codes:{http://snomed.info/sct 710227007}\">Non-specific protein-tyrosine kinase inhibitor</span></p></div>"
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability",
    "valueCode" : "computable"
  },
  {
    "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel",
    "valueCode" : "structured"
  }],
  "url" : "https://www.medizin.uni-greifswald.de/fhir/guideline/cll/ActivityDefinition/RezidivtherapieMitBTKbeiCLL",
  "version" : "Langversion 2.01",
  "name" : "RezidivtherapieMitBTKbeiCLL",
  "title" : "Rezidivtherapie mit BTK-Inhibitor bei CLL",
  "status" : "active",
  "experimental" : false,
  "subjectCodeableConcept" : {
    "coding" : [{
      "system" : "http://hl7.org/fhir/fhir-types",
      "code" : "Patient"
    }]
  },
  "date" : "2025-01-16T09:02:23+00:00",
  "publisher" : "https://www.leitlinienprogramm-onkologie.de/leitlinien/s3-leitlinie-zur-diagnostik-therapie-und-nachsorge-fuer-patienten-mit-einer-chronischen-lymphatischen-leukaemie-cll",
  "description" : "Rezidivtherapie mit BTK-Inhibitor bei CLL",
  "kind" : "MedicationRequest",
  "code" : {
    "coding" : [{
      "system" : "http://snomed.info/sct",
      "code" : "432102000",
      "display" : "Administration of substance (procedure)"
    }]
  },
  "productCodeableConcept" : {
    "coding" : [{
      "system" : "http://snomed.info/sct",
      "code" : "710227007",
      "display" : "Non-specific protein-tyrosine kinase inhibitor"
    }]
  }
}